保定市中医院 深耕中医药事业 书写惠民创新答卷 "十四五"以来，保定市中医院锚定国家级中医药传承创新发展试验区建设目标，紧扣公立医院改革与高 质量发展示范项目要求，将国家中医药传承创新发展部署落到实处，在服务提质、区域协同、文化传播 等方面深耕细作，交出了一份扎实务实的惠民答卷。 （来源：河北日报） 转自：河北日报 医疗服务提质增效，筑牢健康保障根基。以夯实中医药服务能力为核心，全力构建国家级中医优势专科 ——内分泌科，省级中医优势专科——康复科、肾病科、老年病科、心血管科、眼科、治未病科中医药 特色鲜明的专科集群；通过优化中医优势病种诊疗方案30个、临床路径29项，推广中医适宜技术75项和 中医护理技术30项，引进国家级、省级名中医，中医药特色专家64名，门诊量较2020年增长122.31%； 持续推进院内制剂研发与科研成果转化，完成中药制剂注册14种，新增备案2种，成果转化3种，中医药 服务创新能力实现整体跃升。 京津冀协同发力，构建跨域发展新格局。成为中国康复研究中心紧密型医联体成员单位，康复医疗收入 增长538.52%；门诊人次增长381.46%，住院人次增长149.09%；与北京中医药大学东直门医院 ...

Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]